Might losartan reduce sudden cardiac death in diabetic patients with hypertension?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 38 citations in OpenAlex.

1. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.Journal of human hypertension · 2007
   Trial
2. Managing Hypertension in the elderly: What's new?American journal of preventive cardiology · 2020
   Review
3. Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines.Drugs · 2018
   Review
4. Antihypertensive drug therapy.Annals of translational medicine · 2018
   Article
5. Managing Hypertension in Patients Aged 75 Years and Older.Current hypertension reports · 2017
   Review
6. Managing Hypertension in the Elderly: What is Different, What is the Same?Current hypertension reports · 2017
   Review
7. Blood Pressure Goals and Targets in the Elderly.Current treatment options in cardiovascular medicine · 2015
   Article
8. Commentary on recent guidelines for treating hypertension.Archives of medical science : AMS · 2014
   Article
9. Treatment of systemic hypertension.American journal of cardiovascular disease · 2012
   Article
10. Medical reversal: why we must raise the bar before adopting new technologies.The Yale journal of biology and medicine · 2011
    Article

Corrections and comments

• Commented on by
  LIFE: losartan versus atenolol.2003
• Comment on
  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.2002
• Comment on
  Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.2003

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as